IsoEnergy Acquires Additional Securities in Premier American Uranium Inc.

IsoEnergy Ltd. (“IsoEnergy”, or the “Company”) (NYSE American: ISOU) (TSX: ISO)is pleased to announce that it has acquired (the “Transaction”) 2,135,760 common shares (the “PUR Common Shares”) of Premier American Uranium Inc. (“PUR”) and warrants to acquire an additional 2,708,627 PUR Shares in consideration for the issuance of an aggregate of 100,000 common shares of […]

First Citizens BancShares, Inc. Announces Date of Fourth Quarter 2025 Earnings Call

First Citizens BancShares, Inc. (“BancShares”) (NASDAQ: FCNCA) today announced that it will report its financial results for the quarter ended December 31, 2025, before the U.S. financial markets open on Friday, January 23, 2026. https://mma.prnewswire.com/media/1719150/First_Citizens_BancShares__Logo.jpg A conference call and webcast will be held to discuss BancShares' financial results at 9 a.m. Eastern time on the

SOLAI Limited Announces Results of Extraordinary General Meeting

SOLAI Limited (NYSE: SLAI) (previously traded under “BTCM”) (“SOLAI” or the “Company”), a leading technology-drivencryptocurrency infrastructure company, today announced the results of its extraordinary general meeting of shareholders (the “EGM”) held on December 29, 2025. At the EGM, the shareholders of the Company passed the resolution increasing the authorised share capital of the Company to

Profound Medical Corp. Announces Closing of Private Placement

(TSX:PRN),(NASDAQ:PROF), TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”). Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of

Partners Value Investments L.P. Announces Renewal of Normal Course Issuer Bids

(TSX-V:PVF-UN),(TSX-V:PVF-UN),(TSX-V:PVF-U),(TSX-V:PVF.U),(TSX-V:PVF-PU), TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”) (TSX VENTURE: PVF) announced today that it has received approval from the TSX Venture Exchange (the “Exchange”) to renew its normal course issuer bids (collectively, the “Bids”) to purchase: (i) up to 35,256,779 of its nonâ€voting equity limited partnership units (the

Profound Medical Corp. Announces Closing of Private Placement

Profound Medical Corp. Announces Closing of Private Placement GlobeNewswire December 30, 2025 TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”). Pursuant to the Offering, the Company

Partners Value Investments L.P. Announces Renewal of Normal Course Issuer Bids

Partners Value Investments L.P. Announces Renewal of Normal Course Issuer Bids GlobeNewswire December 30, 2025 TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”) (TSX VENTURE: PVF) announced today that it has received approval from the TSX Venture Exchange (the “Exchange”) to renew its normal course issuer bids (collectively, the “Bids”)

Saia to Announce Fourth Quarter 2025 Results on February 10, 2026

Saia to Announce Fourth Quarter 2025 Results on February 10, 2026 GlobeNewswire December 30, 2025 JOHNS CREEK, Ga., Dec. 30, 2025 (GLOBE NEWSWIRE) — Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, announced that it will release its quarterly financial results before the market opens

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE

(NASDAQ:RARE), NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE GlobeNewswire December 30, 2025 NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle

Scroll to Top